Biocryst Pharmaceuticals (BCRX) Operating Expenses (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Operating Expenses for 17 consecutive years, with $119.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 10.32% year-over-year to $119.8 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 billion (up 149.11% YoY), and the FY2025 full-year result was $533.8 million, up 17.78% from the prior year.
• Operating Expenses fell to $119.8 million in Q2 2026 per BCRX's latest filing, from $858.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $858.0 million in Q1 2026 and bottomed at $93.3 million in Q3 2022.
• Historically, Operating Expenses has averaged $156.6 million across 5 years, with a median of $114.6 million in 2024.
• The widest YoY moves for Operating Expenses: up 590.24% in 2026, down 10.32% in 2026.
• Over 5 years, Operating Expenses stood at $125.9 million in 2022, then advanced by 8.12% to $136.1 million in 2023, then decreased by 0.02% to $136.0 million in 2024, then grew by 7.44% to $146.2 million in 2025, then declined by 18.05% to $119.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $119.8 million, $858.0 million, and $146.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.